Physiological Responses to a Natural Antioxidant Flavonoid Mixture, Silymarin, in BALB/c Mice: II. Alterations in Thymic Differentiation Correlate with Changes in c-myc Gene Expression

Abstract

Silymarin is a mixture of bioactive flavonoids isolated from the seeds and fruits of Milk Thistle [Silybum marianum (L.) Gaertner]. We tested the hypothesis that exposure to silymarin will modulate differentiation and cell selection in the thymus via alterations in gene expression. Male BALB/c mice were treated intraperitoneally once daily for five days with 0, 10, 50 or 250 mg/kg of silymarin. Flow cytometric examination of thymic lymphocyte populations showed that the absolute numbers of CD4⁺ and CD8⁺ positive T-lymphocytes were increased by silymarin. The c-myc proto-oncogene is important in controlling differentiation and functions of thymocytes. Treatment with silymarin resulted in increased c-myc expression in the thymus. In contrast, the expressions of IL-2 and IL-4 were decreased by silymarin, while MHC II expression did not change. These results indicate that in vivo exposure to silymarin influences phenotypic selection processes in the thymus at doses that may be encountered in natural medicinal use. Further studies investigating the effects of silymarin on the immune system are warranted.

Silymarin - thymus - T-lymphocytes - CD4 - CD8 - c-myc - cytokines - Silybum marianum - Asteraceae

References

• 1 Middleton E, Kandaswami C, Theoharides T C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer.  Pharmacol Rev. 2000;  52 673-751
• 2 Hahn G, Lehmann H D, Kurten M, Uebel H, Vogel G. On the pharmacology and toxicology of silymarin, and antihepatotoxic active principle from Silybum marianum .  Arzneim-Forsch/Drug Res. 1968;  18 698-704
• 3 Shi Z, Wakil A E, Rockey D C. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses.  Proc Natl Acad Sci USA. 1997;  94 10 663-8
• 4 Lang I, Deak G Y, Nekam K, Muzes G Y, Gonzalez-Cabello R, Gergely P, Feher J. Hepatoprotective and immunomodulatory effects of antioxidant therapy.  Acta Med Hung. 1988;  45 287-95
• 5 Agoston M, Cabello R G, Blazovics A, Feher J, Vereckei A. The effect of amiodarone and/or antioxidant treatment on splenocyte blast transformation.  Clin Chim Acta. 2001;  303 87-94
• 6 Meroni P L, Barcellini W, Borghi M O, Vismara A, Ferraro G, Ciani D, Zanussi C. Silybin inhibition of human T-lymphocyte activation.  Int J Tissue React. 1988;  10 177-81
• 7 Atluru S, Atluru D. Evidence that genistein, a protein-tyrosine kinase inhibitor, inhibits CD 28 monoclonal-antibody-stimulated human T cell proliferation.  Transplantation. 1991;  51 448-50
• 8 Zi X, Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin.  Biochem Biophys Res Commun. 1999;  263 528-36
• 9 Kang S N, Lee M H, Kim K M, Cho D, Kim T S. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C.  Biochem Pharmacol. 2001;  61 1487-95
• 10 Broussad-Diehl C, Bauer S R, Scheuermann R H. A role for c-myc in the regulation of thymocyte differentiation and possible positive selection.  J Immunol. 1996;  156 3141-50
• 11 Campodónico A, Collado E, Ricci R, Pappa H, Segall A, Pizzorno M T. Dissolution test for silymarin tablets and capsules.  Drug Dev Ind Pharm. 2001;  27 261-5
• 12 Letteron P, Labbe G, Degott C, Berson A, Fromenty B, Delaforge M, Larrey D, Pessayre D. Mechanism for the protective effects of silymarin against carbon tetrachloride-induced lipid peroxidation and hepatotoxicity in mice. Evidence that silymarin acts both as an inhibitor of metabolic activation and as a chain-breaking antioxidant.  Biochemical Pharmacology. 1990;  39 2027-34
• 13 He Q, Osuchowski M F, Johnson V J, Sharma R P. Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: I. Induction of transforming growth factor β₁ and c-myc in liver with marginal effects on other genes.  Planta Medica. 2002;  68 676-9
• 14 Johnson V J, Sharma R P. Gender-dependent immunosuppression following subacute exposure to fumonisin B₁ .  International Immunopharmacology. 2001;  1 2023-34
• 15 Sakai K, Li Y, Shirakawa T, Kitagawa Y, Hirose G. Induction of major histocompatibility complex class I molecules on human neuroblastoma line cells by a flavonoid antioxidant.  Neurosci Lett. 2001;  298 127-30
• 16 Douglas N C, Jacobs H, Bothwell A L, Hayday A C. Defining the specific physiological requirements for c-Myc in T cell development.  Nat Immunol. 2001;  2 307-15
• 17 Rudolph B, Hueber A O, Evan G I. Reversible activation of c-Myc in thymocytes enhances positive selection and induces proliferation and apoptosis in vitro .  Oncogene. 2000;  19 1891-900
• 18 Mariathasan S, Ho S S, Zakarian A, Ohashi P S. Degree of ERK activation influences both positive and negative thymocyte selection.  Eur J Immunol. 2000;  30 1060-8
• 19 Ferrer I, Blanco R, Carmona M, Puig B. Phosphorylated c-MYC expression in Alzheimer’s disease, Pick’s disease, progressive supranuclear palsy and corticobasal degeneration.  Neuropathol Appl Neurobiol. 2001;  27 343-51
• 20 Mulroy T, Sen J. p38 MAP kinase activity modulates αβ T cell development.  Eur J Immunol. 2001;  31 3056-63
• 21 Bassiri H, Carding S R. A requirement for IL-2/IL-2 receptor signaling in intrathymic negative selection.  J Immunol. 2001;  166 5945-54